苹果酸卡博替尼（XL184 S-malate）是一种高效的多靶点受体酪氨酸激酶抑制剂，对VEGFR2、c-Met、Kit、Axl和Flt3的IC50值分别为0.035、1.3、4.6、7和11.3 nM。
|
英文别名 (English Synonym) |
Cabozantinib malate (XL184) |
|
中文名称 (Chinese Name) |
卡博替尼苹果酸盐 |
|
靶点 (Target) |
c-MET |
|
通路 (Pathway) |
Protein Tyrosine Kinase |
|
CAS号 (CAS NO.) |
1140909-48-3 |
|
分子式 (Formula) |
C32H30FN3O10 |
|
分子量 (Molecular Weight) |
635.59 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16. PMID: 21926191.
